Literature DB >> 9553088

Identification of intron and exon sequences involved in alternative splicing of insulin receptor pre-mRNA.

A Kosaki1, J Nelson, N J Webster.   

Abstract

The insulin receptor exists as two isoforms, A and B, that result from alternative splicing of exon 11 in the primary transcript. We have shown previously that the alternative splicing is developmentally and hormonally regulated. Consequently, these studies were instigated to identify sequences within the primary RNA transcript that regulate the alternative splicing. Minigenes containing exons 10, 11, and 12 and the intervening introns were constructed and transfected into HepG2 cells, which contain both isoforms of the insulin receptor. The cells were able to splice the minigene transcript to give both A (- exon 11) and B-like (+ exon 11) RNAs. A series of internal deletions within intron 10 were tested for their ability to give A and B RNAs. Intron 10 contained two sequences that modulated exon 11 inclusion; a 48-nucleotide purine-rich sequence at the 5' end of intron 10 that functions as a splicing enhancer and causes an increase in exon 11 inclusion, and a 43-nucleotide sequence at the 3' end of intron 10 upstream of the branch point sequence that favors skipping of exon 11. Increasing the length of the polypyrimidine tract at the 3' end of intron 10 caused exon 11 to be spliced constitutively, indicating that a weak splice site is required for alternative splicing. Finally, point mutations, insertions, and deletions within exon 11 itself were able to regulate inclusion of the exon both positively and negatively.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9553088     DOI: 10.1074/jbc.273.17.10331

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  Requirements for mini-exon inclusion in potato invertase mRNAs provides evidence for exon-scanning interactions in plants.

Authors:  C G Simpson; P E Hedley; J A Watters; G P Clark; C McQuade; G C Machray; J W Brown
Journal:  RNA       Date:  2000-03       Impact factor: 4.942

2.  Characterization of proliferative effects of insulin, insulin analogues and insulin-like growth factor-1 (IGF-1) in human lung fibroblasts.

Authors:  M Warnken; U Reitzenstein; A Sommer; M Fuhrmann; P Mayer; H Enzmann; U R Juergens; K Racké
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-10-06       Impact factor: 3.000

Review 3.  Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.

Authors:  Peter Sazani; Ryszard Kole
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

4.  Natural variation in ARF18 gene simultaneously affects seed weight and silique length in polyploid rapeseed.

Authors:  Jing Liu; Wei Hua; Zhiyong Hu; Hongli Yang; Liang Zhang; Rongjun Li; Linbin Deng; Xingchao Sun; Xinfa Wang; Hanzhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-31       Impact factor: 11.205

5.  Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing.

Authors:  Sharan Paul; Warunee Dansithong; Dongho Kim; John Rossi; Nicholas J G Webster; Lucio Comai; Sita Reddy
Journal:  EMBO J       Date:  2006-08-31       Impact factor: 11.598

6.  Multi-level regulation of PKCδI alternative splicing by lithium chloride.

Authors:  Deena Bader; Rekha S Patel; Ashley Lui; Chetna Thawani; Rea Rupani; Gitanjali Vidyarthi; Niketa A Patel
Journal:  Mol Cell Biol       Date:  2020-12-07       Impact factor: 4.272

7.  Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

Authors:  F Frasca; G Pandini; P Scalia; L Sciacca; R Mineo; A Costantino; I D Goldfine; A Belfiore; R Vigneri
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

8.  Muscleblind proteins regulate alternative splicing.

Authors:  Thai H Ho; Nicolas Charlet-B; Michael G Poulos; Gopal Singh; Maurice S Swanson; Thomas A Cooper
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

9.  A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1.

Authors:  Amin Haghighat Jahromi; Lien Nguyen; Yuan Fu; Kali A Miller; Anne M Baranger; Steven C Zimmerman
Journal:  ACS Chem Biol       Date:  2013-03-20       Impact factor: 5.100

10.  SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing.

Authors:  Supriya Sen; Indrani Talukdar; Nicholas J G Webster
Journal:  Mol Cell Biol       Date:  2008-12-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.